{
    "clinical_study": {
        "@rank": "157960", 
        "arm_group": [
            {
                "arm_group_label": "PTNS and solifenacin", 
                "arm_group_type": "Active Comparator", 
                "description": "PTNS bladder neuromodulation weekly for 12 treatments; solifenacin 5 mg capsule daily for 15 weeks"
            }, 
            {
                "arm_group_label": "PTNS and placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "PTNS bladder neuromodulation weekly for 12 treatments; placebo 1 capsule daily for 15 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The null hypothesis for this study is that the combination of solifenacin and Percutaneous\n      Tibial Nerve Stimulation (PTNS) is not different from PTNS alone. However the investigators\n      anticipate a 20% improvement in patients receiving combination therapy as measured by the\n      OAB-q (Overactive Bladder questionnaire) scores."
        }, 
        "brief_title": "Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Overactive Bladder", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Overactive"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 18 years of age or older\n\n          2. history of overactive bladder\n\n          3. history of inadequate response to prior or current treatment with anti-    muscarinic\n             medication, or unacceptable side effects from higher dose of   anti-muscarinic\n             medication\n\n          4. PTNS-naive\n\n          5. willing to discontinue the use of anti-muscarinic agents for 2 weeks before start of\n             study medication (\"washing out\")\n\n          6. able to swallow and retain oral medication\n\n          7. able and willing to participate in the full duration of the study\n\n          8. able to read and write (health outcomes questionnaires are self-administered)and\n             understand instructions related to study procedures and give written informed consent\n\n          9. OAB-q (items 1-8) score of 30 or higher\n\n        Exclusion Criteria:\n\n          1. presence of cardiac pacemaker and/or defibrillator\n\n          2. history of urinary retention\n\n          3. history of gastric retention\n\n          4. uncontrolled narrow angle glaucoma\n\n          5. any unstable, serious co-existing medical condition(s) including, but not limited to,\n             myocardial infarction,coronary bypass surgery, unstable angina, cardiac arrhythmias,\n             clinically evident congestive heart failure, or cerebrovascular accident within 3\n             months prior to Screening visit\n\n          6. abnormal liver function test (greater than 3 times the upper limit of normal for\n             alanine aminotransferase [ALT], aspartate aminotransferase [AST], or alkaline\n             phosphatase [ALP]); or bilirubin > 3 times the upper limit of normal\n\n          7. history of any illness (including psychiatric) that, in the opinion of the\n             investigator, might confound the results of the study or pose additional risk to the\n             subject\n\n          8. known hypersensitivity to solifenacin\n\n          9. participation in any investigational or marketed drug trial within the 30 days prior\n             to the first dose of study drug or any time during the study period\n\n         10. pregnancy or trying to become pregnant\n\n         11. breast-feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764893", 
            "org_study_id": "BSU-SOL-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "PTNS and solifenacin", 
                "description": "12 weekly treatments with percutaneous tibial nerve stimulation with 5 mg of solifenacin; an additional 4 weeks of solifenacin for a total of 15 weeks of study drug.", 
                "intervention_name": "PTNS plus solifenacin", 
                "intervention_type": "Other", 
                "other_name": "Vesicare"
            }, 
            {
                "arm_group_label": "PTNS and placebo", 
                "description": "12 weekly treatments with percutaneous tibial nerve stimulation with placebo; an additional 4 weeks of placebo for a total of 15 weeks of placebo.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Overactive Bladder", 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Watertown", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02472"
                }, 
                "name": "Bay State Clinical Trials, Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Solifenacin and Percutaneous Tibial Nerve Stimulation in Patients With Refractory Overactive Bladder", 
        "overall_official": {
            "affiliation": "Bay State Clinical Trials, Inc.", 
            "last_name": "H. David Mitcheson, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Overactive Bladder Questionnaire, items 1-8 only", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline in Overactive Bladder Questionnaire at 11 weeks."
            }, 
            {
                "measure": "Overactive Bladder Questionnaire, items 1-8 only", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline in Overactive Bladder Questionnaire at 15 weeks."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764893"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To measure changes in frequency, urgency, urge incontinence episodes, nocturia and urine volume (one day of each 3-day diary)", 
                "measure": "3-day micturition diary", 
                "safety_issue": "No", 
                "time_frame": "Change in Bladder diary from Baseline to 5 weeks."
            }, 
            {
                "description": "To measure changes in frequency, urgency, urge incontinence episodes, nocturia and urine volume (one day of each 3-day diary)", 
                "measure": "3-day micturition diary", 
                "safety_issue": "No", 
                "time_frame": "Change in Bladder diary from Baseline to 11 weeks."
            }, 
            {
                "description": "To measure changes in frequency, urgency, urge incontinence episodes, nocturia and urine volume (one day of each 3-day diary)", 
                "measure": "3-day micturition diary", 
                "safety_issue": "No", 
                "time_frame": "Change in Bladder diary from Baseline to 15 weeks."
            }, 
            {
                "measure": "Urgency Perception Scale (questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "Changes in Urgency Perception from Baseline to 11 weeks."
            }, 
            {
                "measure": "Urgency Perception Scale (questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "Changes in Urgency Perception from Baseline to 15 weeks."
            }
        ], 
        "source": "Bay State Clinical Trials, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bay State Clinical Trials, Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014", 
        "why_stopped": "Enrolling too slowly due to insurance plans no longer covering the cost of the Percutaneous\n    Tibial Nerve Stimulation treatment."
    }
}